Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHAMAL
2019-001924-37Phase 4Unknown
- Sponsor
- AstraZeneca
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of benralizumab and budesonide in eosinophilic asthma (EA) (2 arms), sponsored by AstraZeneca. Primary endpoint: Proportion of patients with reduced Symbicort maintenance dose at Week 32. Status: unknown.
02
Drugs
benralizumabbudesonide
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on 2019-001924-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001924-37.